Original Article
Avascular Retinal Pigment Epithelial Detachment
Treated With Intravitreal Ranibizumab: 3-Year Follow-up
Imran Akram, Amjad Akram
DOI
10.36351/pjo.v35i4.917 Pak J Ophthalmol 2019, Vol. 35, No. 4
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See
end of article for authors
affiliations …..……………………….. Correspondence
to: Dr. Imran Akram Consultant Ophthalmic & Vitreoretinal Surgeon St Helens & Knowsley Teaching Hospitals NHS
Trust Email: imranakram2020@gmail.com |
Purpose: To evaluate the long-term effect of intravitreal
Ranibizumab on visual acuity and the morphology of retinal pigment epithelial
detachments, not associated with choroidal neovascularization. Study Design: Retrospective case series. Place and Duration of Study: Ophthalmology Department at St Helens
& Knowsley Teaching Hospital, United Kingdom, between 2011 and 2013. Material and Methods: This was a retrospective case series looking at case
notes and retinal imaging of 12 patients with avascular pigment epithelial
detachment. At pre-treatment baseline all patients had demographic
characteristics recorded such as date of birth, sex, race and a general
health questionnaire. These patients were treated with three injections of
Ranibizumab at monthly interval. Corrected visual acuity and PED height were
compared at 3, 6, 12, 24 and 36 months post injection. Results: At 6 months post-injection PED height decreased by
up to 50% as compared to baseline height and this was largely maintained over
36 months post-injection. Two eyes showed subsequent increase in PED height
to baseline level although further treatment was not performed. Visual acuity
did not improve in any case although was maintained at baseline in 8 cases
for 36 months and reduced in 4 cases due to central macular atrophic changes
observed over 36 months. No case of RPE rip was seen in this series. Conclusion: Avascular PED treated with intravitreal Ranibizumab
shows some reduction of the height of the PED, which in turn reduced the risk
of a spontaneous RPE rip. Key
Words: Avascular Pigment Epithelial Detachment,
Ranibizumab, Choroidal neovascularisation. |
Retinal pigment epithelial detachment
(PED) is a common manifestation in several retinal conditions including age-related
macular degeneration1. Based on retinal imaging as well as clinical
examination, PEDs can be classified as drusenoid, serous or vascular2,3,4.
Vascularised PEDs, as the name suggest, are associated with choroidal
neovascularization (CNV). Drusenoid and serous PEDs may or may not have an
associated CNV. Anti-VEGF therapy has a well proven role in the treatment of
vascularized PED5,6. Less well established is the beneficial effect
of anti-VEGF therapy in those PEDs where a CNV is not clearly present. Large
serous PEDs were excluded from phase 3 clinical trials such as TAP, ANCHOR and
MARINA7,8,9 trials. As such these trials cannot be relied upon to
provide management strategies for these lesions.
Development of a rip in a PED can result
in permanent damage to central vision10,11. Such a rip is often
spontaneous although intravitreal therapy can also precipitate an RPE rip12,13.
It is therefore desirable to reduce the height of a PED in order to minimize
the risk of a rip. Furthermore, a longstanding PED presumably interferes with
the nutrition to the RPE and photoreceptors and thus early flattening of the
PED or reducing its height was an important treatment rationale in this study. No universally agreed guidelines exist on the
treatment of PEDs not associated with a CNV. One study14 looked
specifically at the role of the anti-VEGF agent, Ranibizumab (Lucentis) in
non-vascularised PEDs but the follow-up period in that study was 12 months. The
purpose of this study was to look at the long term effects of 3 Ranibizumab
injections given in eyes with non-vascularised PEDs. The effects were monitored
for up to 36 months and to date this is the longest follow-up published for
this sub-set of treated patients.
MATERIAL AND METHODS
In this study, we looked at eyes with
fovea involving avascular PED of at least 100 microns height, which were
treated with 3 injections of intravitreal Ranibizumab between 2011 and 2013. All
patients had a baseline visual acuity of at least 50 ETDRS letters. Absence of
associated choroidal neovascularization (CNV) was established by structural OCT
and fluorescein angiography (Heidelberg Spectralis). Patients with co-existing
macular pathology such as diabetic macular edema, CSCR, retinal angiomatous
proliferation (RAP) and epiretinal membrane were not treated with anti-VEGF.
At pre-treatment baseline, all patients
had demographic characteristics recorded such as date of birth, sex, race and a
general health questionnaire. Best
corrected visual acuity was recorded using ETDRS letter score. Volume OCT
scanning of the macula was performed. Fluorescein angiography was performed in
all patients to rule out presence of CNV. OCT Angiography was not available at
the time. The patients were then
evaluated by a retina specialist to consider suitability for Ranibizumab
treatment. PED height was measured using the inbuilt calipers in the OCT
software (see Fig). Maximum vertical distance between Bruchs membrane and the
RPE was used as a measure of baseline PED height. The PED was classified as
drusenoid or serous based on the reflectivity of the sub-RPE space on OCT
examination. Informed consent was obtained for the full course of treatment.
All patients received three Ranibizumab injections at four weekly intervals
according to departmental protocol. No supplementary injections were performed
in these patients as we did not consider the Royal College of Ophthalmologists
wet AMD guidelines to be applicable to these cases. The aim of treatment was to
reduce height of the PED in order to prevent the possibility of a future rip as
well as to stabilize and improve visual acuity.
The primary outcome measures were effect
on reduction in PED height and effect on visual acuity over the course of 3
years following the initial loading dose of 3 Ranibizumab injections. Following
3 initial injections all patients were monitored for up to 36 months. At each
visit visual acuity was measured using ETDRS letters. PED height was measured
on structural OCT scan.
RESULTS
Twelve eyes of 12 patients met the
inclusion criteria for this study. There were 7 females and 5 males. Median age
was 77 (age range 58-90). At baseline, 9 PEDs were considered serous based on
hyporeflectivity on OCT scanning. 3 PEDs were considered drusenoid. Mean
baseline visual acuity was 59.66 ETDRS letters (range 50-69). Mean PED height
was 281 microns (range 90-410).
Table 1. Baseline characteristics.
Median age in years (range) |
77 (58-90) |
Gender (male: female) |
5:7 |
PED morphology (serous: drusenoid) |
9:3 |
Visual acuity Mean in ETDRS letters
(range) |
59.66 (50-69) |
PED height Mean in microns (range) |
281 (90-410) |
Table 2: Measurements of PED mean height in microns
(SD) and mean best corrected visual acuity BCVA in ETDRS letters (SD).
|
Baseline |
Month
3 |
Month
6 |
Month
12 |
Month
24 |
Month
36 |
BCVA |
59.66
(14.66) |
58.55
(15.12) |
54.78
(14.99) |
54.34
(14.81) |
53.85 (14.96) |
53.12 (15.32) |
PED Height |
281 (148.92) |
216.22 (135.66) |
142.34 (119.32) |
111.02 (120.73) |
98.34 (129.45) |
96.66 (131.22) |
Fig. 1: OCT scan of
same eye (A) before any treatment, showing “dry” PED. (B) 6 months after 3rd
injection showing almost complete resolution of PED. (C) 36 months after
injections showing complete PED flattening and RPE atrophy.
PED height reduced by 64.78 microns at
month 3 following the third Ranibizumab injection. From there onwards, the
reduction in height was gradual and a further mean reduction of 96.56 microns
was noted between month 3 and month 36 post-injection. Least reduction in
height was noted in the drusenoid PEDs although these eyes showed the most
stable VA. Five eyes with serous PED showed complete resolution of the PED with
no recurrence during the follow-up period. Two eyes with serous PED showed a
recurrent increase in PED height to baseline levels between months 12 and 24. BCVA
showed a gradual mean decrease of 6.54 ETDRS letters over the 36 months of
follow-up. No eye showed development of CNV throughout the study period.
DISCUSSION
The pathogenesis of pigment epithelial
detachment (PED) is not completely understood. Anatomical apposition of the RPE
to the underlying Bruch’s membrane is crucial for the nutritional support of
the outer retina. The forces maintaining this adhesion are not fully clear. A
decrease in overall conductivity across Bruch’s membrane resulting in reduced
fluid exchange between the choroid and RPE is considered to be a widely
accepted underlying mechanism of PED formation15, although it may be
likely that drusenoid and serous PEDs could have different pathogenesis16.
Inflammatory mediators17 as well as VEGF18 have been
implicated in the increased permeability across Bruch’s membrane.
For ease of description, we would like to
introduce the terms “dry PED” to denote avascular PEDs, as distinguished from
“wet PED” which are clearly associated with choroidal neovascularization as
shown by structural OCT and Fluorescein/Indocyanine Green angiography. Dry PEDs
include drusenoid PEDs and serous PEDs which show no features of CNV. There is
no universally accepted treatment strategy for dry PEDs. This study represents
the longest published follow-up (3 years) of eyes with avascular PED treated
with Ranibizumab in a real world setting. In 12 eyes of 12 patients, 3
intravitreal injections of Ranibizumab were performed to treat Dry age-related
PED. Maximum reduction in PED height was seen in the first 6 months followed by
a more gradual mean reduction. This effect was sustained in 10 eyes over 3
years whereas 2 eyes showed recurrence of the PED. In 5 eyes complete
flattening of the PED was observed. Beneficial effect on visual acuity was less
encouraging as compared to treating fibrovascular PEDs with Ranibizumab19,20.
However, 8 eyes maintained their baseline visual acuity. Interestingly these
included the 2 eyes which developed recurrent PED. Four eyes showed a gradual
decline in visual acuity over 36 months. All of these were eyes in which the
PED had completely flattened and outer retinal degenerative changes gradually
developed.
Our study findings compare favorably with
a similar study from Vienna14 although Ritter et al’s follow-up
period was 12 months compared to our 36 month follow-up. They also recruited 12
patients but half of these were treated with up to 6 Ranibizumab injections
over 6 months. They also concluded that Ranibizumab treatment can reduce PED
height and volume but the effect was not maintained over the 12 months period
of their study. Other studies have found limited benefit of anti-VEGF in
bringing about complete resolution of the PED element of wet AMD21
whereas one large series22 has correlated the anatomic response of
treatment to baseline PED height, associated vascularization and also the type
of anti-VEGF used.
The findings of this retrospective case
series suggest structural benefit and visual stability in some patients with
age-related “dry” PEDs treated with intravitreal Ranibizumab. This further suggests that VEGF may indeed have
a role in the pathogenesis of age-related pigment epithelial detachments even
when no structural or angiographic features of choroidal neovascularization are
present.
COMPLIANCE WITH ETHICAL STANDARDS
We have no financial disclosure and no
conflict of interest in this case.
Informed consent was obtained from the
patient in order to use his images in this publication.
REFERENCES
1. Zayit-Soudry
S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv
Ophthalmol. 2007; 52: 227-243.
2. Hartnett
ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment
epithelial detachments associated with drusen. Grafes Arch Clin Exp Ophth.
1992; 230: 11-19.
3. Poliner
LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment
epithelial detachments in age-related macular degeneration. Ophthalmology,
1986; 93: 543-551.
4. Gass
JD. Serous retinal pigment epithelial detachment with a notch: a sign of
occult choroidal neovascularization. Retina. 1984; 4: 205-220.
5. Arias
L. Treatment of retinal pigment epithelial detachment with antiangiogenic
therapy. Clinical Ophthalmol. 2010; 4: 369-374.
6. Chevreaud
O, Oubraham H, Cohen SY. Ranibizumab for vascularized pigment epithelial
detachment: 1-year anatomic and functional results. Graefes Arch Clin Exp
Ophthalmol. 2017; 255 (4): 743–51.
7. Photodynamic therapy of subfoveal choroidal
neovascularisation in age-related macular degeneration with verteporfin:
one-year results of 2 randomized clinical trials–TAP report. Treatment of
age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol. 1999; 117: 1329–1345.
8. Rosenfeld
PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab
for neovascular age related macular degeneration. N Engl J Med. 2006; 355:
1419–1431.
9. Brown
DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S,
ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular
age-related macular degeneration. N Engl J Med. 2006; 355: 1432–1444.
10. Decker
WL, Sanborn GE, Ridley M. Retinal pigment epithelial tears. Ophthalmology.
1983; 207: 27-35.
11. Bakri SJ, Kitzmann AS. Retinal pigment
epithelial tear after intravitreal ranibizumab. Am J Ophthalmol. 2007; 143: 505–507.
12. Chang LK, Sarraf D. Tears of the retinal
pigment epithelium: an old problem in a new era. Retina. 2007; 27: 523-534.
13. Ronan SM, Yoganathan P, Chien FY, Corcostegui
IA, Blumenkranz MS, Deramo VA, Elner SG, et al. Retinal pigment epithelium tears after
intravitreal injection of bevacizumab (Avastin) for Neovascular age-related
macular degeneration. Retina. 2007; 27:
535-540.
14. Ritter
M, Bolz M, Sacu S, Deak GG, Kiss C, Pruente C, Schmidt-Erfurth UM. Effect
of intravitreal Ranibizumab in avascular pigment epithelial detachment. Eye,
2010; 24: 962-968.
15. Moore
DJ, Hussain AA, Marshall J. Age-related variation in the hydraulic
conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 1995; 36:
1290–1297.
16. Sheraidah
G, Stein metz R, Maguire J, Pauleikhoff D, Marshall J, Bird AC. Correlation
between lipids extracted from Bruch’s membrane and age. Ophthalmology. 1993; 100:
47-51.
17. Hollyfield
JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG,
Perez VL. Oxidative damage-induced inflammation initiates age-related
macular degeneration. Nat Med. 2008; 14: 194–198.
18. Oh H,
Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y.
The potential angiogenic role of macrophages in the formation of choroidal
neovascular membranes. Invest Ophthalmol Vis Sci. 1999; 40: 1891–1898.
19. Arora
S, McKibbin M. One-year outcome after intravitreal ranibizumab for large,
serous pigment epithelial detachment secondary to age-related macular
degeneration. Eye, 2011; 25: 1034-1038.
20. Panos
GD, Gatzioufas Z, Petropoulos IK, Dardabounis D, Thumann G, Hafezi F. Effect
of ranibizumab on serous and vascular pigment epithelial detachments associated
with exudative age-related macular degeneration. Drug Des Devel Ther. 2013; 7: 565–9.
21. Cho
HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of Pigment Epithelial
Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related
Macular Degeneration.Am J Ophthalmol. 2016 Jun; 166: 112-119.
22. Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors Influencing
the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular
Degeneration. Am J Ophthalmol. 2015 Oct; 160 (4): 732-8
Author’s Affiliation
Dr. Imran Akram
Consultant Ophthalmic & Vitreoretinal
Surgeon
St Helens & Knowsley Teaching
Hospitals NHS Trust
Marshalls Cross Road, St Helens WA9 3DA,
United Kingdom
Brigadier Amjad Akram
Consultant Ophthalmic Surgeon
Combined Military Hospital, Kharian Cantt,
District Gujrat
Author’s Contribution
Dr. Imran Akram
Data collection, Manuscript writing.
Brigadier Amjad Akram
Manuscript writing, literature review,
critical analysis.